633 related articles for article (PubMed ID: 21815614)
21. Estimation of drug solubility in polymers via differential scanning calorimetry and utilization of the fox equation.
Haddadin R; Qian F; Desikan S; Hussain M; Smith RL
Pharm Dev Technol; 2009; 14(1):18-26. PubMed ID: 18825543
[TBL] [Abstract][Full Text] [Related]
22. An investigation into the effect of spray drying temperature and atomizing conditions on miscibility, physical stability, and performance of naproxen-PVP K 25 solid dispersions.
Paudel A; Loyson Y; Van den Mooter G
J Pharm Sci; 2013 Apr; 102(4):1249-67. PubMed ID: 23359268
[TBL] [Abstract][Full Text] [Related]
23. Preparation of glass solutions of three poorly water soluble drugs by spray drying, melt extrusion and ball milling.
Patterson JE; James MB; Forster AH; Lancaster RW; Butler JM; Rades T
Int J Pharm; 2007 May; 336(1):22-34. PubMed ID: 17174493
[TBL] [Abstract][Full Text] [Related]
24. Formation Mechanism of Coamorphous Drug-Amino Acid Mixtures.
Jensen KT; Larsen FH; Cornett C; Löbmann K; Grohganz H; Rades T
Mol Pharm; 2015 Jul; 12(7):2484-92. PubMed ID: 26057950
[TBL] [Abstract][Full Text] [Related]
25. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam.
Prabhu S; Ortega M; Ma C
Int J Pharm; 2005 Sep; 301(1-2):209-16. PubMed ID: 16046087
[TBL] [Abstract][Full Text] [Related]
26. Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles.
Fini A; Cavallari C; Ospitali F
Eur J Pharm Biopharm; 2008 Sep; 70(1):409-20. PubMed ID: 18621516
[TBL] [Abstract][Full Text] [Related]
27. Investigations on the effect of different cooling rates on the stability of amorphous indomethacin.
Karmwar P; Boetker JP; Graeser KA; Strachan CJ; Rantanen J; Rades T
Eur J Pharm Sci; 2011 Oct; 44(3):341-50. PubMed ID: 21884789
[TBL] [Abstract][Full Text] [Related]
28. Molecular Dynamics and Physical Stability of Coamorphous Ezetimib and Indapamide Mixtures.
Knapik J; Wojnarowska Z; Grzybowska K; Jurkiewicz K; Tajber L; Paluch M
Mol Pharm; 2015 Oct; 12(10):3610-9. PubMed ID: 26301858
[TBL] [Abstract][Full Text] [Related]
29. The impact of surface- and nano-crystallisation on the detected amorphous content and the dissolution behaviour of amorphous indomethacin.
Priemel PA; Grohganz H; Gordon KC; Rades T; Strachan CJ
Eur J Pharm Biopharm; 2012 Sep; 82(1):187-93. PubMed ID: 22683936
[TBL] [Abstract][Full Text] [Related]
30. Relating hydrogen-bonding interactions with the phase behavior of naproxen/PVP K 25 solid dispersions: evaluation of solution-cast and quench-cooled films.
Paudel A; Nies E; Van den Mooter G
Mol Pharm; 2012 Nov; 9(11):3301-17. PubMed ID: 23009610
[TBL] [Abstract][Full Text] [Related]
31. A comparative study of spray-dried and freeze-dried hydrocortisone/polyvinyl pyrrolidone solid dispersions.
Dontireddy R; Crean AM
Drug Dev Ind Pharm; 2011 Oct; 37(10):1141-9. PubMed ID: 21615280
[TBL] [Abstract][Full Text] [Related]
32. Crystal forms of naproxen.
Song JS; Sohn YT
Arch Pharm Res; 2011 Jan; 34(1):87-90. PubMed ID: 21468919
[TBL] [Abstract][Full Text] [Related]
33. In vitro and in vivo comparison between crystalline and co-amorphous salts of naproxen-arginine.
Kasten G; Lobo L; Dengale S; Grohganz H; Rades T; Löbmann K
Eur J Pharm Biopharm; 2018 Nov; 132():192-199. PubMed ID: 30266670
[TBL] [Abstract][Full Text] [Related]
34. The Role of Glass Transition Temperatures in Coamorphous Drug-Amino Acid Formulations.
Kissi EO; Kasten G; Löbmann K; Rades T; Grohganz H
Mol Pharm; 2018 Sep; 15(9):4247-4256. PubMed ID: 30020794
[TBL] [Abstract][Full Text] [Related]
35. Coamorphization combined with complexation enhances dissolution of lurasidone hydrochloride and puerarin with synchronized release.
Wang S; Heng W; Wang X; He X; Zhang Z; Wei Y; Zhang J; Gao Y; Qian S
Int J Pharm; 2020 Oct; 588():119793. PubMed ID: 32827676
[TBL] [Abstract][Full Text] [Related]
36. Performance comparison between crystalline and co-amorphous salts of indomethacin-lysine.
Kasten G; Nouri K; Grohganz H; Rades T; Löbmann K
Int J Pharm; 2017 Nov; 533(1):138-144. PubMed ID: 28947246
[TBL] [Abstract][Full Text] [Related]
37. Crystallization of amorphous indomethacin during dissolution: effect of processing and annealing.
Greco K; Bogner R
Mol Pharm; 2010 Oct; 7(5):1406-18. PubMed ID: 20459092
[TBL] [Abstract][Full Text] [Related]
38. Preparation and evaluation of solid dispersions of piroxicam and Eudragit S100 by spherical crystallization technique.
Maghsoodi M; Sadeghpoor F
Drug Dev Ind Pharm; 2010 Aug; 36(8):917-25. PubMed ID: 20180658
[TBL] [Abstract][Full Text] [Related]
39. Improvement of dissolution rate of piroxicam by inclusion into MCM-41 mesoporous silicate.
Ambrogi V; Perioli L; Marmottini F; Giovagnoli S; Esposito M; Rossi C
Eur J Pharm Sci; 2007 Nov; 32(3):216-22. PubMed ID: 17826966
[TBL] [Abstract][Full Text] [Related]
40. Exploring the physical stability of three nimesulide-indomethacin co-amorphous systems from the perspective of molecular aggregates.
Wang M; Liu S; Jia L; Zhang J; Du S; Gong J
Eur J Pharm Sci; 2020 Apr; 147():105294. PubMed ID: 32147483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
